Monograph
J05AP01 - Ribavirin |
Propably not porphyrinogenic |
PNP |
Important Information
Side effects like diarrhoea, nausea, vomiting, abdominal pains and infections can be confused with an acute porphyric attack and may potentially be porphyrinogenic.
Side effects
Very common side effects of ribavirin in combination with interferon alpha are diarrhoea, nausea, vomiting, abdominal pains, anorexia, depression, anxiety, insomnia and infections. These side effects can be confused with an acute porphyric attack and may potentially trigger an acute porphyric attack.
Rationale
Ribavirin is not a substrate, inhibitor or inducer of CYP450 enzymes. No pharmacokinetic porphyrinogenic effects are suspected.
Chemical description
Synthetic ribofuranozyl nucleoside
Therapeutic characteristics
Ribavirin in combination with boceprevir and peg-interferon alpha is indicated for the treatment of chronic hepatitis C genotype 1.
It is administered orally.
Metabolism and pharmacokinetics
Ribavirin is metabolized either by phosphorylation or by deribosylation and amide hydrolysis to triazole carboxylation and cleared by the kidneys (SPC).
Ribavirin is not a substrate, inhibitor or inducer of CYP450 enzymes (SPC) and there are no drug-drug interactions involving CYP450 enzymes (Lexi-Interact, SPC)
References
| # | Citation details | PMID |
|---|---|---|
| * | Government bodies | |
| 1. |
|
|
| * | Drug interaction databases | |
| 2. | Lexi-Interact in UpToDate. Ribavirin: Drug interaction program.
|
|
| * | Summary of Product Characteristics | |
| 3. | The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). (Rebetol).
|
|
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Netherlands
United Kingdom
Denmark
Norway
Poland© NAPOS 2024